Abstract:The development of chimeric antigen receptor (CAR) T cells enables us to leverage the potency of T cells, redirecting them against tumour cells and reshaping the treatment algorithms for lymphoid malignancies. CAR T cells have proven capable of inducing complete remission in many patients, and even cure a subset of them. Ongoing research seeks to deepen our understanding of the factors influencing their efficacy to enhance the next generation of CAR T‐cell products and refine therapeutic approaches. This review synthesizes key results from clinical trials, insights from the correlative studies and current research endeavours, aiming to translate those lessons into practice. Summary Autologous chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of lymphoid malignancies, leading to the approval of CD19‐CAR T cells for B‐cell lymphomas and acute leukaemia, and more recently, B‐cell maturation antigen‐CAR T cells for multiple myeloma. The long‐term follow‐up of patients treated in the early clinical trials demonstrates the possibility for long‐term remission, suggesting a cure. This is associated with a low incidence of significant long‐term side effects and a rapid improvement in the quality of life for responders. In contrast, other types of immunotherapies require prolonged treatments or carry the risk of long‐term side effects impairing the quality of life. Despite impressive results, some patients still experience treatment failure or ultimately relapse, underscoring the imperative to improve CAR T‐cell therapies and gain a better understanding of their determinants of efficacy to maximize positive outcomes. While the next‐generation of CAR T cells will undoubtingly be more potent, there are already opportunities for optimization when utilizing the currently available CAR T cells. This review article aims to summarize the current evidence from clinical, translational and fundamental research, providing clinicians with insights to enhance their understanding and use of CAR T cells.

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment

Prospects and challenges for use of CAR T cell therapies in solid tumors

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR T-cell immunotherapy: The path from the by-road to the freeway?

A long way to the battlefront: CAR T cell therapy against solid cancers.

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Bright future or blind alley? CAR-T cell therapy for solid tumors

CAR-T cell therapy: current limitations and potential strategies

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

CAR T-cell immunotherapy of B-cell malignancy: the story so far

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

CAR T cell therapy: Current limitations and advancements in treating solid tumors

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment